Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Aviga vs Sutent in Healthy Volunteers
NCT05218616Phase 1Unknown
- Sponsor
- NatiVita
- Start
- Jan 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sunitinib in renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by NatiVita. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time zero to the last measurable concentration. Status: unknown.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05218616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218616.